{
    "clinical_study": {
        "@rank": "136105", 
        "arm_group": [
            {
                "arm_group_label": "C\u2192 M \u2192 M+ P \u2192 C + P", 
                "arm_group_type": "Other", 
                "description": "Mycophenolate mofetil (C) tablet twice a day every 12 hours for two weeks. Mycophenolate sodium (M) tablet twice a day every 12 hours for two weeks. Pantoprazole tablet (P) once a day in the morning for two weeks."
            }, 
            {
                "arm_group_label": "M \u2192 M + P \u2192 C + P \u2192 C", 
                "arm_group_type": "Other", 
                "description": "Mycophenolate mofetil (C) tablet twice a day every 12 hours for two weeks. Mycophenolate sodium (M) tablet twice a day every 12 hours for two weeks. Pantoprazole tablet (P) once a day in the morning for two weeks."
            }, 
            {
                "arm_group_label": "M + P\u2192 C + P \u2192 C\u2192 M", 
                "arm_group_type": "Other", 
                "description": "Mycophenolate mofetil (C) tablet twice a day every 12 hours for two weeks. Mycophenolate sodium (M) tablet twice a day every 12 hours for two weeks. Pantoprazole tablet (P) once a day in the morning for two weeks."
            }, 
            {
                "arm_group_label": "C+ P\u2192 C \u2192 M\u2192 M+ P", 
                "arm_group_type": "Other", 
                "description": "Mycophenolate mofetil (C) tablet twice a day every 12 hours for two weeks. Mycophenolate sodium (M) tablet twice a day every 12 hours for two weeks. Pantoprazole tablet (P) once a day in the morning for two weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The object of this pharmakokinetic study is to analyze wether pantoprazole as a proton pump\n      inhibitor influences the bioavailability of two different tablet formulations of\n      mycophenolic acid applied either as mycophenolate mofetil or mycophenolate Sodium."
        }, 
        "brief_title": "Influence of Pantoprazole to the Bioavailability of Myfortic\u00ae and CellCept\u00ae", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Immunosuppressive Medication After Renal Transplantation", 
            "Concomitant Medication After Renal Transplantation"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients >18 years old\n\n          -  patients who are on stable immunosuppressive pre-treatment for at least one month\n             with Cyclosporin A, Myfortic\u00ae or CellCept\u00ae with/without corticosteroids\n\n          -  renal transplantation, at least 6 months prior study inclusion\n\n          -  suitable and willing to switch treatment according to the study plan\n\n          -  women of childbearing potential must have a negative serum pregnancy test before\n             study start and effective contraception must be used (method with PEARL index < 1%)\n\n        Exclusion Criteria:\n\n          -  patients with renal function < 30ml/min (using Cockcroft Gault formula)\n\n          -  patients who are not on stable treatment with enzyme inductors or enzymes for one\n             month before study start\n\n          -  known anamnestic hypersensitivity to one of the investigational products or drugs\n             with similar chemical structure and to other components of the investigational\n             products, respectively\n\n          -  patients on treatment with clopidogrel\n\n          -  acute rejection < 1 month before study inclusion\n\n          -  patients who are HIV positive, hepatitis C virus (HCV) positive, HBsAg positive\n\n          -  patients with gastrointestinal disorders which could affect resorption\n\n          -  pregnancy and/or lactation\n\n          -  drug or alcohol abuse in patient's history\n\n          -  patients with a history of psychological illness or condition, so it might interfere\n             with the patient's ability to understand the requirements, consequences, possible\n             outcome of the study and patients who are not willing to give valid informed consent\n             to the study\n\n          -  patients with insufficient co-operation with the clinical investigator (e.g.\n             suspicion of non-compliance)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01801280", 
            "org_study_id": "CERL 080A DE 20 T", 
            "secondary_id": "2010-021275-92"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "C\u2192 M \u2192 M+ P \u2192 C + P", 
                    "M \u2192 M + P \u2192 C + P \u2192 C", 
                    "M + P\u2192 C + P \u2192 C\u2192 M", 
                    "C+ P\u2192 C \u2192 M\u2192 M+ P"
                ], 
                "description": "Daily dose: 720mg, 1080mg, 1440mg. Application either alone or together with Pantozol\u00ae.", 
                "intervention_name": "Mycophenolate sodium", 
                "intervention_type": "Drug", 
                "other_name": "Myfortic\u00ae"
            }, 
            {
                "arm_group_label": [
                    "C\u2192 M \u2192 M+ P \u2192 C + P", 
                    "M \u2192 M + P \u2192 C + P \u2192 C", 
                    "M + P\u2192 C + P \u2192 C\u2192 M", 
                    "C+ P\u2192 C \u2192 M\u2192 M+ P"
                ], 
                "description": "Daily dose: 40mg. Application together with either CellCept\u00ae or Myfortic\u00ae .", 
                "intervention_name": "Pantoprazole", 
                "intervention_type": "Drug", 
                "other_name": "Pantozol\u00ae"
            }, 
            {
                "arm_group_label": [
                    "C\u2192 M \u2192 M+ P \u2192 C + P", 
                    "M \u2192 M + P \u2192 C + P \u2192 C", 
                    "M + P\u2192 C + P \u2192 C\u2192 M", 
                    "C+ P\u2192 C \u2192 M\u2192 M+ P"
                ], 
                "description": "Daily dose: 1000mg, 1500mg, 2000mg. Application either alone or with Pantozol\u00ae .", 
                "intervention_name": "Mycophenolate mofetil", 
                "intervention_type": "Drug", 
                "other_name": "Cellcept\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Mycophenolate mofetil", 
                "Mycophenolic Acid", 
                "Pantoprazole", 
                "Proton Pump Inhibitors"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "immunosuppressive medication", 
            "mycophenolic acid", 
            "interaction", 
            "proton pump inhibitor", 
            "pantoprazole", 
            "renal transplant patients", 
            "pharmacokinetics", 
            "pharmacodynamics", 
            "bioavailability"
        ], 
        "lastchanged_date": "February 26, 2013", 
        "location": {
            "contact": {
                "email": "klemens.budde@charite.de", 
                "last_name": "Klemens Budde, Prof Dr", 
                "phone": "+49 30 450 154 086"
            }, 
            "contact_backup": {
                "email": "olesja.rissling@charite.de", 
                "last_name": "Olesja Rissling", 
                "phone": "+49 30 450 154 125"
            }, 
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany", 
                    "zip": "10117"
                }, 
                "name": "Charit\u00e9 Hospital Campus Mitte"
            }, 
            "investigator": {
                "last_name": "Klemens Budde, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "4", 
        "official_title": "Single Center, Open Label, Cross-over Study in Maintenance Renal Transplant Patients to Evaluate the Bioavailability of CellCept\u00ae (Mycophenolate Mofetil) in Comparison to Myfortic\u00ae (Enteric Coated Mycophenolate Sodium) With/Without the Proton Pump Inhibitor Pantozol\u00ae (Pantoprazole).", 
        "overall_contact": {
            "email": "klemens.budde@charite.de", 
            "last_name": "Klemens Budde, Prof Dr", 
            "phone": "+49 30 450 154 086"
        }, 
        "overall_contact_backup": {
            "email": "olesja.rissling@charite.de", 
            "last_name": "Olesja Rissling", 
            "phone": "+49 30 450 154 125"
        }, 
        "overall_official": {
            "affiliation": "Charite University, Berlin, Germany", 
            "last_name": "Klemens Budde, Prof Dr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluation of the bioavailability (as measured by 12h AUC) of mycophenolic acid in stable renal transplant patients under immunosuppressive maintenance therapy after application of CellCept\u00ae alone or in combination with Pantozol\u00ae; Myfortic\u00ae alone or in combination with Pantozol\u00ae.\nFor pharmacokinetic and pharmacodynamic parameters 12 samples (before, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h after oral drug administration) from venous blood will be collected.", 
            "measure": "Bioavailability of mycophenolic acid (measured by AUC)", 
            "safety_issue": "No", 
            "time_frame": "Study duration for each patient: 2 months. After 10-14 days of drug intake blood samples for full AUC will be collected and on the next day new treatment starts. Every patient has to visit the study centre four times for approximately 12 hours."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01801280"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Charite University, Berlin, Germany", 
            "investigator_full_name": "Klemens Budde", 
            "investigator_title": "Professor Dr Klemens Budde", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Analysis of additional pharmacokinetic parameters, such as maximum concentration, average concentration, minimum concentration, time to Cmax, apparent clearance of mycophenolic acid and its metabolite mycophenolic acid glucuronide.", 
                "measure": "Analysis of additional pharmacokinetic parameters", 
                "safety_issue": "No", 
                "time_frame": "Study duration for each patient: 2 months. After 10-14 days of drug intake blood samples for full AUC will be collected and on the next day new treatment starts. Every patient has to visit the study centre four times for approximately 12 hours."
            }, 
            {
                "description": "Analysis if IMPDH activity and the related pharmacodynamic parameters as maximum activity, minimum activity, average activity, maximum inhibition", 
                "measure": "Analysis of pharmacodynamic parameters", 
                "safety_issue": "No", 
                "time_frame": "Study duration for each patient: 2 months. After 10-14 days of drug intake blood samples for full AUC will be collected and on the next day new treatment starts. Every patient has to visit the study centre four times for approximately 12 hours."
            }, 
            {
                "description": "Analysis of safety and tolerability, in particular analysis of gastrointestinal discomfort (using two standardized questionnaires), infections, leucopenia, anemia, thrombocytopenia, renal function using serum creatinine and glomerular filtration rate (Cockcroft-Gault), ciclosporin blood levels (before and two hours after administration), incidence of biopsy-proven acute rejections and graft loss.\nBefore oral drug administration additionally blood samples for blood chemistry, hematology and urine for urinalysis will be collected.", 
                "measure": "Analysis of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Study duration for each patient: 2 months. After 10-14 days of drug intake every patient has to visit the study center 4 times for approximately 12 hours."
            }
        ], 
        "source": "Charite University, Berlin, Germany", 
        "sponsors": {
            "collaborator": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Klemens Budde", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}